Inogen (NASDAQ: INGN) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its peers? We will compare Inogen to related businesses based on the strength of its dividends, institutional ownership, earnings, risk, analyst recommendations, profitability and valuation.
This table compares Inogen and its peers’ net margins, return on equity and return on assets.
Institutional & Insider Ownership
66.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 5.3% of Inogen shares are owned by insiders. Comparatively, 10.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Inogen and its peers gross revenue, earnings per share (EPS) and valuation.
Inogen’s peers have higher revenue and earnings than Inogen. Inogen is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Inogen has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Inogen’s peers have a beta of 1.06, meaning that their average share price is 6% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Inogen and its peers, as provided by MarketBeat.
Inogen currently has a consensus price target of $90.80, suggesting a potential downside of 3.80%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.41%. Given Inogen’s peers stronger consensus rating and higher possible upside, analysts plainly believe Inogen has less favorable growth aspects than its peers.
Inogen peers beat Inogen on 9 of the 13 factors compared.
Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.